James N.  Woody net worth and biography

James Woody Biography and Net Worth

James N. Woody, M.D., Ph.D has more than 25 years of pharmaceutical research and management expertise.

He has served as our Chief Executive Officer and as a director since the closing of the business combination in November 2020. Dr. Woody has served as the CEO of 180 since July 2020, and as a director of 180 Life Sciences since September 2020.

Dr. Woody was a founder and served as Chairman of the Board of Directors for Viracta Pharmaceuticals, a lymphoma therapeutic company (2014 to 2020). With the company undergoing a reverse merger into a public company, he resigned his Board member position and continues as a Board observer.

He has served in a variety of health and management roles including as President of Roche Bioscience, and CSO and Senior Vice President of R&D for Centocor.

At Centocor, Jim was part of the team that discovered Remicade, used to treat arthritis and which is now one of the best-selling drugs in the world.

He served as Commanding Officer and Director at the US Naval Medical Research and Development Command in Bethesda, Maryland.

In this role he was responsible for the surveillance, detection and therapy for all biologic warfare agents and infectious diseases in the First Gulf War; he was awarded the US Navy Legion of Merit for his service.

He holds an MD from Loma Linda University, and trained in pediatric immunology at Duke University and Boston Children’s Hospital (Harvard).

He further holds a PhD in Immunology from the University of London and has co-authored more than 140 publications.

What is James N. Woody's net worth?

The estimated net worth of James N. Woody is at least $2.31 thousand as of May 18th, 2023. Dr. Woody owns 220 shares of Flag Ship Acquisition stock worth more than $2,312 as of December 6th. This net worth estimate does not reflect any other assets that Dr. Woody may own. Learn More about James N. Woody's net worth.

How do I contact James N. Woody?

The corporate mailing address for Dr. Woody and other Flag Ship Acquisition executives is 3000 EL CAMINO REAL, BLDG 4, STE 200, PALO ALTO, CA, 94306. Flag Ship Acquisition can also be reached via phone at (650) 507-0669 and via email at [email protected]. Learn More on James N. Woody's contact information.

Has James N. Woody been buying or selling shares of Flag Ship Acquisition?

James N. Woody has not been actively trading shares of Flag Ship Acquisition in the last ninety days. Most recently, on Thursday, May 18th, James N. Woody bought 210 shares of Flag Ship Acquisition stock. The stock was acquired at an average cost of $195.70 per share, with a total value of $41,097.00. Following the completion of the transaction, the chief executive officer now directly owns 220 shares of the company's stock, valued at $43,054. Learn More on James N. Woody's trading history.

Who are Flag Ship Acquisition's active insiders?

Flag Ship Acquisition's insider roster includes Donald McGovern, Jr. (Director), Ozan Pamir (CFO), Quan Vu (COO), and James Woody (CEO). Learn More on Flag Ship Acquisition's active insiders.

James N. Woody Insider Trading History at Flag Ship Acquisition

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/18/2023Buy210$195.70$41,097.00220View SEC Filing Icon  
12/9/2021Buy3$16,226.00$48,678.00View SEC Filing Icon  
See Full Table

James N. Woody Buying and Selling Activity at Flag Ship Acquisition

This chart shows James N Woody's buying and selling at Flag Ship Acquisition by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Flag Ship Acquisition Company Overview

Flag Ship Acquisition logo
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Read More

Today's Range

Now: $10.51
Low: $10.49
High: $11.70

50 Day Range

MA: $16.87
Low: $9.47
High: $25.80

2 Week Range

Now: $10.51
Low: $6.60
High: $174.60

Volume

960,703 shs

Average Volume

857,553 shs

Market Capitalization

$224.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05